IOHEXOL

Post-LOE

iohexol

GE HealthCare

ANDAINJECTION, ORAL, RECTALSOLUTION

Approved

Nov 2025

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

IOHEXOL (iohexol) by GE HealthCare is x-ray contrast activity [moa]. Approved for radiographic contrast agent [epc]. First approved in 2025.

Drug data last refreshed Yesterday

Mechanism of Action

X-Ray Contrast Activity

Pharmacologic Class:

Radiographic Contrast Agent

Indications (1)

Radiographic Contrast Agent

Clinical Trials (4)

NCT03869983N/ACompleted

Relative Bioavailability of CE-Iohexol (Captisol-enabled™ Iohexol) Injection and Omnipaque™ Injection

Started Apr 2019

24 enrolled

Contrast-induced NephropathyCoronary Angiography

NCT02884089Phase 1Completed

A Study of the Effect of Abemaciclib on Metformin and Iohexol in Healthy Participants

Started Aug 2016

40 enrolled

Healthy

NCT01790139N/ACompleted

Oral Iohexol for Fecal/Fluid Tagging for CT Colonography: A Study to Improve Image Quality by Preventing Colonic Bubbles

Started Feb 2013

84 enrolled

Colorectal Neoplasms

NCT01214993Phase 1Completed

A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects

Started Oct 2010

38 enrolled

Infections, Human Immunodeficiency Virus and Tuberculosis

Worked on IOHEXOL at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.